The biggest litigation impacting the healthcare industry
Above the Law and Lake Whillans take a deep dive into multibillion-dollar disputes involving pay-for-delay agreements, opioids, and other areas.
Above the Law and Lake Whillans take a deep dive into multibillion-dollar disputes involving pay-for-delay agreements, opioids, and other areas.
While the ultimate litigation effects of the COVID-19 pandemic remain to be seen, the current high-profile healthcare claims are as varied as product liability and mass tort actions, antitrust and patent cases, and disputes involving the Affordable Care Act.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Lake Whillans is providing financial relief to insurance companies that offered plans on the Affordable Care Act’s health insurance exchanges and are now impaired by the government’s delay in making promised so-called “risk corridor payments.”
When it comes to fighting disease, Michael Shuster takes things personally...
Corporate venture investment has emerged as an important alternative to more traditional healthcare funding avenues. However, there's still a dearth of information about their activity.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
This independent editorial series on healthcare and the law is sponsored by Lake Whillans, a distressed venture capital and litigation finance firm that helps companies facing litigation or arbitration. As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift […]
Not too long ago, it didn’t take much for someone with an idea for a new medical device to rake in the early-stage funding. Investors have been a bit more discerning over the past decade, to say the least, and by and large they remain so, according to K&L Gates’ Michael Hedge, who’s been around long enough to […]
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind. But when the going gets tough, the tough consider strategic alternatives. Stuart Falber and Belinda Juran, […]
The life sciences — particularly in biotechnology and pharmaceuticals — are among the very few industries where companies insist on industry-specialized advisors. The complex life cycle of a life sciences product demands a broad range of legal and business expertise across many practice specialties, combined with deep scientific knowledge. The stakes are increasing particularly when […]
Throughout the year Lake Whillans, with the help of MedCity News, has explored two key issues for healthcare investors and entrepreneurs: trust and reliability. We’ve helped bring to light some harrowing war stories of partnerships gone bad. We’ve also asked healthcare leaders in the trenches about the best ways to operate in the modern healthcare […]